Segmentation of the Gastroparesis Drugs market by type categorizes pharmacologic and device‑based therapies that address delayed gastric emptying through distinct mechanisms. Prokinetic agents constitute the largest share, roughly 55 % of market value, with sub‑categories including dopamine‑D2 antagonists (e.g., metoclopramide), motilin receptor agonists (e.g., erythromycin), and newer 5‑HT4 agonists (e.g., prucalopride). Their prevalence reflects clinical reliance on agents that directly accelerate gastric motility. Antiemetic drugs, accounting for about 20 % of sales, comprise serotonin‑5‑HT3 antagonists (ondansetron) and NK‑1 receptor antagonists (aprepitant), which mitigate nausea and vomiting—key symptomatic burdens. Gastric electrical stimulation (GES) devices represent a niche but high‑margin segment (~15 %), offering a non‑pharmacologic option for refractory cases; adoption is limited by procedural costs and reimbursement uncertainty. Emerging biologics and novel small‑molecule agents, still in late‑stage trials, occupy the remaining 10 % and are projected to reshape the taxonomy as efficacy data mature. Each type segment contributes uniquely to total market size: volume‑driven prokinetics anchor revenue, while antiemetics and GES provide complementary growth vectors that diversify the overall portfolio.
